Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791523 | 0.91 | SMN1; SMN2 (0.47) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL6184569 | 0.85 | NPC1 (0.59) | SMN1; SMN2LMNAMETAP1TP53ALDH1A1 | |
| SCHEMBL5224142 | 0.85 | POLB (0.60) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL2733475 | 0.83 | SMN1; SMN2 (0.42) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL6076256 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL2880191 | 0.81 | LMNA (0.54) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL4470283 | 0.80 | NPC1 (0.42) | SMN1; SMN2POLBLMNARXFP1METAP1 | |
| SCHEMBL2829176 | 0.80 | POLB (0.56) | POLBRXFP1TP53ALDH1A1HPGD | |
| SCHEMBL5227369 | 0.79 | NPC1 (0.64) | SMN1; SMN2LMNAMETAP1TP53ALDH1A1 | |
| SCHEMBL5222427 | 0.79 | HDAC1 (0.53) | SMN1; SMN2RXFP1METAP1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2220042-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2010-08-25 | — | — | EP | disclosed |
| WO-2009063054-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | 4SC AG (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2060565-A1 | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases | 4SC AG (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-7501451-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7071219-B2 | Mono-acylated o-phenylendiamines derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | FERTIG GEORG | 2006-04-27 | — | — | US | disclosed |
| EP-1592667-A2 | NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069803-A2 | MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065734-A1 | NOVEL BIFUNCTIONAL COMPOUNDS WHICH INHIBIT PROTEIN KINASES AND HISTONE DEACETYLASES | HDAC1, HDAC11, MAP2K2 | SMN1; SMN2 3494/4885POLB 1081/4885LMNA 1301/4885 |
| US-20060089403-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC10, HDAC11 | SMN1; SMN2 4107/4885POLB 1025/4885LMNA 2940/4885 |
| US-20040162317-A1 | Mono-acylated o-phenylendiamines derivatives | HDAC1, HDAC11, HDAC10 | SMN1; SMN2 4060/4885POLB 1328/4885LMNA 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.